The Role of Scalp Acupuncture for Relieving the Chronic Pain of Degenerative Osteoarthritis: A Pilot Study of Egyptian Women
ABSTRACT Osteoarthritis (OA) is a common chronic and painful condition secondary to deterioration of cartilage. OA-related pain can be managed pharmacologically together with complementary therapies, such as acupuncture.
The aim of this trial was to evaluate the effectiveness of Yamamoto New Scalp Acupuncture (YNSA) for relieving pain associated with OA in Egyptian women.
At the Female Outpatient Pain Clinic, of the National Research Centre, in Cairo, Egypt, between March 2008 and June 2009, 30 females (ages 27-80) presenting with chronic pain caused by OA were studied.
The affected YNSA points were treated for 20 minutes in a single session.
Pain was assessed by a visual analogue scale (VAS) prior to, and 1 hour after, the intervention.
PREINTERVENTION VAS SCORES WERE: 3-10 (mean 7.43±1.9; P>0.05). Postintervention VAS scores ranged from 0 to 8 (mean 3.37±2.1) with a statistically significant positive correlation between these scores and pretreatment values (P=0.01). Postintervention VAS scores were significantly related to pain locations. Post-hoc analysis showed statistically significant lower postintervention VAS scores for cervical OA, compared to those of lumbosacral OA.
YNSA acupuncture is effective in immediate pain relief among females suffering from degenerative OA.
- SourceAvailable from: Fred Wolfe[Show abstract] [Hide abstract]
ABSTRACT: To provide a single source for the best available estimates of the US prevalence of and number of individuals affected by osteoarthritis, polymyalgia rheumatica and giant cell arteritis, gout, fibromyalgia, and carpal tunnel syndrome, as well as the symptoms of neck and back pain. A companion article (part I) addresses additional conditions. The National Arthritis Data Workgroup reviewed published analyses from available national surveys, such as the National Health and Nutrition Examination Survey and the National Health Interview Survey. Because data based on national population samples are unavailable for most specific rheumatic conditions, we derived estimates from published studies of smaller, defined populations. For specific conditions, the best available prevalence estimates were applied to the corresponding 2005 US population estimates from the Census Bureau, to estimate the number affected with each condition. We estimated that among US adults, nearly 27 million have clinical osteoarthritis (up from the estimate of 21 million for 1995), 711,000 have polymyalgia rheumatica, 228,000 have giant cell arteritis, up to 3.0 million have had self-reported gout in the past year (up from the estimate of 2.1 million for 1995), 5.0 million have fibromyalgia, 4-10 million have carpal tunnel syndrome, 59 million have had low back pain in the past 3 months, and 30.1 million have had neck pain in the past 3 months. Estimates for many specific rheumatic conditions rely on a few, small studies of uncertain generalizability to the US population. This report provides the best available prevalence estimates for the US, but for most specific conditions more studies generalizable to the US or addressing understudied populations are needed.Arthritis & Rheumatology 01/2008; 58(1):26-35. DOI:10.1002/art.23176 · 7.76 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Osteoarthritis of the knee is a major cause of disability among adults. Treatment is focused on symptom management, with nonpharmacologic therapies being the preferred first line of treatment. Acupuncture is considered a potentially useful treatment for osteoarthritis. The objective of this article is to review the English-language articles, indexed in MEDLINE or CINAHL, describing randomized, controlled trials of the effects of needle or electroacupuncture on knee osteoarthritis. Ten trials representing 1456 participants met the inclusion criteria and were analyzed. These studies provide evidence that acupuncture is an effective treatment for pain and physical dysfunction associated with osteoarthritis of the knee.Family & community health 07/2008; 31(3):247-54. DOI:10.1097/01.FCH.0000324482.78577.0f · 0.99 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: The STandards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) were published in five journals in 2001 and 2002. These guidelines, in the form of a checklist and explanations for use by authors and journal editors, were designed to improve reporting of acupuncture trials, particularly the interventions, thereby facilitating their interpretation and replication. Subsequent reviews of the application and impact of STRICTA have highlighted the value of STRICTA as well as scope for improvements and revision. To manage the revision process a collaboration between the STRICTA Group, the CONSORT Group and the Chinese Cochrane Centre was developed in 2008. An expert panel with 47 participants was convened that provided electronic feedback on a revised draft of the checklist. At a subsequent face-to-face meeting in Freiburg, a group of 21 participants further revised the STRICTA checklist and planned dissemination. The new STRICTA checklist, which is an official extension of CONSORT, includes 6 items and 17 subitems. These set out reporting guidelines for the acupuncture rationale, the details of needling, the treatment regimen, other components of treatment, the practitioner background and the control or comparator interventions. In addition, and as part of this revision process, the explanations for each item have been elaborated, and examples of good reporting for each item are provided. In addition, the word ‘controlled’ in STRICTA is replaced by ‘clinical’, to indicate that STRICTA is applicable to a broad range of clinical evaluation designs, including uncontrolled outcome studies and case reports. It is intended that the revised STRICTA checklist, in conjunction with both the main CONSORT statement and extension for non-pharmacological treatment, will raise the quality of reporting of clinical trials of acupuncture.Acupuncture in Medicine 06/2010; 28(2):83-93. DOI:10.1136/aim.2009.001370 · 1.50 Impact Factor